公开(公告)号：US20220273809A1

公开(公告)日：2022-09-01

申请号：US17628382

申请日：2020-07-17

Applicant: GENMAB A/S

Inventor： Maarten JANMAAT ,  Nora PENCHEVA ,  Esther Cornelia Wilhelmina BREIJ ,  Julia BOSHUIZEN ,  Daniel Simon PEEPER ,  Ulf FORSSMANN ,  Tahamtan AHMADI ,  Patricia Garrido CASTRO

IPC: A61K47/68 ,  A61P35/00 ,  A61K47/02

Abstract: The present invention relates to conjugates of antibodies and cytotoxic agents for use in treatment of cancer in combination with an inhibitor of PD-1 or PD-L1. The antibodies are directed against Axl.

公开(公告)号：US20220112309A1

公开(公告)日：2022-04-14

申请号：US17559965

申请日：2021-12-22

Applicant: GENMAB A/S

Inventor： Brian ELLIOTT ,  Tahamtan AHMADI ,  Patricia Garrido CASTRO

IPC: C07K16/46 ,  C07K16/28 ,  A61P35/00 ,  A61K31/282

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL ineligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of gemcitabine and oxaliplatin (GemOx).